Files

Download

Download Full Text (456 KB)

Description

Janus kinase inhibitors (JAKi) are novel oral therapy option for rheumatoid arthritis (RA) patients. However, data from the randomized controlled trials (RCTs) found an increased risk of cancer, serious cardiovascular events, blood clots, and death with JAKi. Patients enrolled in RCTs do not represent general patient population in real world. It is essential to complete the body of evidence with real-world data (RWD).

Publication Date

2-21-2024

Relational Format

poster

Systematic Review of Real-World Data: Assessing Cancer, Major Adverse Cardiovascular Events, Venous Thromboembolism, Infection, and Mortality Risk Associated With JAK Inhibitors in Rheumatoid Arthritis Patients in the United States

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.